Sensorion SA
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, whi… Read more
Sensorion SA (ALSEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.332x
Based on the latest financial reports, Sensorion SA (ALSEN) has a cash flow conversion efficiency ratio of -0.332x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.94 Million) by net assets (€56.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sensorion SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sensorion SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sensorion SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sensorion SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Odyssey Marine Exploration Inc
NASDAQ:OMEX
|
0.025x |
|
LIWANLI Innovation Co Ltd
TW:3054
|
-0.056x |
|
INVALDA INVL AB EO-29
F:WTK
|
N/A |
|
TSUKADA GLOBAL HLDGS INC.
F:TVJ
|
N/A |
|
PT Aviana Sinar Abadi Tbk
JK:IRSX
|
-0.014x |
|
EstechPharma Co. Ltd
KQ:041910
|
0.003x |
|
GaeaSoft Corp
KQ:051160
|
0.021x |
|
Karex Berhad
KLSE:5247
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Sensorion SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sensorion SA from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €72.14 Million | €-21.33 Million | -0.296x | +53.30% |
| 2023-12-31 | €33.28 Million | €-21.07 Million | -0.633x | +35.30% |
| 2022-12-31 | €21.87 Million | €-21.41 Million | -0.979x | -299.56% |
| 2021-12-31 | €43.98 Million | €-10.77 Million | -0.245x | -168.93% |
| 2020-12-31 | €58.35 Million | €-5.31 Million | -0.091x | +91.51% |
| 2019-12-31 | €13.21 Million | €-14.17 Million | -1.072x | +69.27% |
| 2018-12-31 | €3.51 Million | €-12.25 Million | -3.489x | -228.29% |
| 2017-12-31 | €7.32 Million | €-7.78 Million | -1.063x | -26.94% |
| 2016-12-31 | €8.59 Million | €-7.19 Million | -0.837x | -112.45% |
| 2015-12-31 | €12.82 Million | €-5.05 Million | -0.394x | -105.53% |
| 2014-12-31 | €-323.20K | €-2.30 Million | 7.130x | +504.41% |
| 2013-12-31 | €-1.20 Million | €-1.42 Million | 1.180x | +103.73% |
| 2012-12-31 | €26.11K | €-826.03K | -31.636x | -- |